Following our confirmation of the impact of PHD2/3 on T-cell activation, our investigation extended to determining whether stabilizing HIF-1α through deletion of PHD2/3 in CD8 T cells would enhance their anti-tumor function in other tumor models. Here, EGLN1 is linked to neoplasm.